Barry Stoler to Chair Board of Advisors at the University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center
Barry Stoler, president of Len Stoler Automotive Group, has been named chair of the Board of Advisors of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).
Stoler, 59, of Owings Mills, Md., is the son of Roslyn and Leonard Stoler, who made an historic $25 million gift in October 2018 to help fund a major expansion of UMGCCC. Their generous gift was the largest philanthropic donation in the history of the University of Maryland Medical Center (UMMC).
Barry Stoler is president of Len Stoler Automotive Group, which owns auto dealerships throughout the Baltimore area and New York. His daughter, Lindsay, was successfully treated for cancer 27 years ago at UMMC, and her recovery has been the inspiration for his family's longtime support of the cancer center. Stoler takes over the helm of the UMGCCC board from Stuart Weitzman, a Baltimore-area businessman who has served as chair for nearly 16 years.
"We are very pleased that Barry has graciously agreed to lead the board as we head into this exciting new phase of growth and development for the cancer center,” said Kevin J. Cullen, MD, the Marlene and Stewart Greenebaum Distinguished Professor of Oncology at the University of Maryland School of Medicine (UMSOM) and director of UMGCCC.
"My sincere thanks to Stuart for his many years of service to the Greenebaum Comprehensive Cancer Center. We are so fortunate to have had such outstanding support from local leaders like Stuart Weitzman, Michael Greenebaum and others. I so appreciate Barry's commitment to our future as we enter this very exciting chapter in our history," Dr. Cullen added.
UMMC plans to build a nine-story, 155,000-square-foot addition to facilitate expansion of the cancer center, which is one of 51 National Cancer Institute (NCI)-designed comprehensive cancer centers in the nation. UMGCCC is a joint entity of the medical center and UMSOM.
"We are pleased that Barry Stoler has agreed to chair the Greenebaum Comprehensive Cancer Center's Board of Advisors," said Dean E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. "We are so very fortunate to have the tremendous support of the Stolers and the Greenebaum's to guide the center into the future."
"I am delighted to welcome Barry as the new chair of the cancer center's Board of Advisors, especially at this pivotal moment in the center's history," said Mohan Suntha, MD, MBA, the Marlene and Stewart Greenebaum Professor of Radiation Oncology at UMSOM and president and chief executive officer of the University of Maryland Medical System (UMMS).
"In that leadership role, he will be a tremendous asset in helping us to meet the challenge of providing cancer patients with the most technologically advanced, compassionate care available anywhere," Dr. Suntha said. "At the same time, he will also be continuing the Stoler family's long tradition of service to the community and the Greenebaum Comprehensive Cancer Center."
The Roslyn and Leonard Stoler Center for Advanced Medicine will provide integrated inpatient and outpatient cancer services and will position UMGCCC to meet the escalating demands for cancer care well into the future. The number of patients served and treatments provided by UMGCCC has tripled in the last 11 years, while the cancer center has operated in roughly the same footprint.
The certificate of need for the new building was filed with the Maryland Health Care Commission Feb. 8, 2019. Once the project is approved by the state and other agencies, officials expect to break ground on the new building in early 2021, with completion in 2024.
"I look forward to doing everything I can to elevate the public profile of the University of Maryland Greenebaum Comprehensive Cancer Center and to promote the outstanding research and clinical work that goes on there every day," said Stoler, who also serves on the campaign committee raising funds for the new building.
About the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is a National Cancer Institute-designated comprehensive cancer center in Baltimore. The center is a joint entity of the University of Maryland Medical Center and University of Maryland School of Medicine. It offers a multidisciplinary approach to treating all types of cancer and has an active cancer research program. It is ranked among the top 20 cancer programs in the nation by U.S. News & World Report. www.umgccc.org.
About University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and more than $540 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System ("University of Maryland Medicine") has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu.